Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

NCT02912949 is registered in ClinicalTrials.gov with Partner Therapeutics, Inc. as lead sponsor.

NCT NCT02912949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02912949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)
Lead sponsor
Partner Therapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 31, 2015
Completion date
December 31, 2026
Enrollment
250 (estimated)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

nrg1 fusion, nsclc harboring nrg1 fusion, pancreatic cancer harboring nrg1 fusion, solid tumours harboring nrg1 fusion